SUMMIT THERAPEUTICS PLC AND THE BANK OF NEW YORK MELLON As Depositary AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES Deposit AgreementDeposit Agreement • February 20th, 2015 • Summit Therapeutics PLC • Pharmaceutical preparations • New York
DEPOSIT AGREEMENT dated as of [Agreementdate] among SUMMIT THERAPEUTICS PLC, a company incorporated under the laws of England and Wales (herein called the Company), THE BANK OF NEW YORK MELLON, a New York banking corporation (herein called the Depositary), and all Owners and Holders (each as hereinafter defined) from time to time of American Depositary Shares issued hereunder.
INDEMNIFICATION AGREEMENTIndemnification Agreement • September 18th, 2020 • Summit Therapeutics Inc. • Pharmaceutical preparations • Delaware
This Agreement is made as of the [_____] day of [_______] 202[_], by and between Summit Therapeutics Inc., a Delaware corporation (the “Corporation”), and [______________] (the “Indemnitee”), a director or officer of the Corporation.
PRESCRIBED CLAUSESSummit Therapeutics PLC • March 30th, 2017 • Pharmaceutical preparations
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 7th, 2023 • Summit Therapeutics Inc. • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of October 13, 2023 by and among Summit Therapeutics Inc., a Delaware corporation, with its principal place of business at 2882 Sand Hill Road, Suite 106, Menlo Park, CA (the “Company”), and the investor named on the signature page hereto (the “Investor”).
PRIVATE & CONFIDENTIAL Ms. Elaine Stracker Dear Elaine Non-Executive Directorship - Letter of AppointmentSummit Therapeutics PLC • April 30th, 2020 • Pharmaceutical preparations
This agreement is conditional on, and shall take effect upon, Admission becoming effective and confirms the main terms and conditions of your appointment to this office. If Admission has not taken place on or before 31 December 2019, this agreement shall lapse and you shall not be appointed as a non-executive director of the Company unless otherwise appointed.
BETWEEN: RECITALSSummit Therapeutics PLC • April 30th, 2020 • Pharmaceutical preparations • England
NOTE PURCHASE AGREEMENTNote Purchase Agreement • April 21st, 2021 • Summit Therapeutics Inc. • Pharmaceutical preparations • New York
This NOTE PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of April 20, 2021 by and among Summit Therapeutics Inc., a Delaware corporation, with its principal place of business at One Broadway, 14th Floor, Cambridge, MA 02142 (the “Company”), and the investor named on Exhibit A hereto (the “Investor”).
DATED 19 OCTOBER 2012 TRANSLATION AWARD FUNDING AGREEMENTTemplate Equity and Revenue • February 27th, 2015 • Summit Therapeutics PLC • Pharmaceutical preparations • England
DATED [•], 2020 SUMMIT THERAPEUTICS INC. and [CONSULTANT] WARRANT AGREEMENTWarrant Agreement • September 18th, 2020 • Summit Therapeutics Inc. • Pharmaceutical preparations • Delaware
1INTERPRETATION 1 2GRANT 9 3ANCILLARY RIGHTS 9 4RIGHTS EXCEPTED AND RESERVED 13 5THIRD PARTY RIGHTS 15 6THE ANNUAL RENT 15 7SERVICES AND SERVICE CHARGE 15 8INSURANCE 20 9RATES AND TAXES 23 10UTILITIES 23 11COMMON ITEMS 24 12VAT 24 13DEFAULT INTEREST...Summit Therapeutics PLC • April 13th, 2018 • Pharmaceutical preparations • England and Wales
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 6th, 2020 • Summit Therapeutics Inc. • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of November 6, 2020 by and among Summit Therapeutics Inc., a Delaware corporation (the “Company”), the investor named in that certain Securities Purchase Agreement, dated November 6, 2020 by and between the Company and Polar Capital Funds plc – Biotechnology Fund, and the investor named in that certain Securities Purchase Agreement, dated November 6, 2020 by and between the Company and Mahkam Zanganeh Revocable Trust (each a “Purchase Agreement” and together the “Purchase Agreements”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreements unless otherwise defined herein.
Dated 23rd December 2017 The Management Team andDiscuva Limited TRANSFER INCENTIVE AGREEMENTIncentive Agreement • April 13th, 2018 • Summit Therapeutics PLC • Pharmaceutical preparations • England and Wales
The Management Team have all provided support to the development of the Relevant Products of the Company and in recognition of this the Company has agreed to pay a transfer incentive payment to the Management Team in the event that the Relevant Products achieve certain milestones in their development and subject to the terms of this agreement.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. DATED 20 September 2017Agreement • April 13th, 2018 • Summit Therapeutics PLC • Pharmaceutical preparations • England and Wales
ContractSummit Corp PLC • December 4th, 2014 • Pharmaceutical preparations • Massachusetts
The licensee(s) identified on the signature page of this agreement (“Licensee”, or “Client”) intends to contract with (please check one)
EQUITY AND REVENUE SHARING AGREEMENT (Seeding Drug Discovery Initiative and Translation Award)Equity and Revenue Sharing Agreement • April 13th, 2018 • Summit Therapeutics PLC • Pharmaceutical preparations • England
DATED 16 July 2014 THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD and SUMMIT CORPORATION PLC and ISIS INNOVATION LIMITED VARIATION AGREEMENTVariation Agreement • December 4th, 2014 • Summit Corp PLC • Pharmaceutical preparations • England and Wales
relating to the Agreement for the Sponsorship of a Research Programme for the development of small molecule modulators of utrophin for the treatment of Duchenne Muscular Dystrophy dated 22 November 2013
DATE [AGREEMENT DATE] Summit Therapeutics plc - and – [NON-EXECUTIVE DIRECTOR NAME] NON-EXECUTIVE DIRECTOR RESTRICTED STOCK UNIT (RSU) AGREEMENT (IN THE FORM OF A NOMINAL COST OPTION)Agreement • April 13th, 2018 • Summit Therapeutics PLC • Pharmaceutical preparations
WHEREAS the Company wishes to grant to the RSU Holder a restricted stock unit (RSU) in the form of a nominal-cost option on the terms set out in this Agreement, and this RSU is intended to comply with the requirements of Section 409A of the Code.
DATED 6 DECEMBER 2019 SUMMIT THERAPEUTICS PLC and MAKY ZANGANEH & ASSOCIATES, INC. CONSULTANT WARRANT AGREEMENTConsultant Warrant Agreement • December 6th, 2019 • Summit Therapeutics PLC • Pharmaceutical preparations
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 17th, 2018 • Summit Therapeutics PLC • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of December 14, 2018 by and among Summit Therapeutics plc, a public limited company incorporated in England and Wales with the Registrar of Companies of England and Wales, with its principal place of business at 136a Eastern Avenue, Milton Park, Abingdon, Oxfordshire OX14 4SB, United Kingdom (the “Company”), and the investor named on Exhibit A hereto (the “Investor”).
DATED 6 DECEMBER 2019 PLACING AGREEMENT RELATING TO A PLACING OF UP TO 9,221,400 ORDINARY SHARES AND 1,383,210 WARRANTS TO SUBSCRIBE FOR ORDINARY SHARES IN SUMMIT THERAPEUTICS PLCAgreement • December 6th, 2019 • Summit Therapeutics PLC • Pharmaceutical preparations • England and Wales
OPTION AGREEMENTOption Agreement • January 30th, 2015 • Summit Corp PLC • Pharmaceutical preparations • England and Wales
DATED 16th November 2015 - and - - and - VARIATION AGREEMENT relating to the Option Agreement in relation to the intellectual property rights arising in the performance of the Sponsored Research Agreement and Research Field dated 22 November 2013Variation Agreement • May 12th, 2016 • Summit Therapeutics PLC • Pharmaceutical preparations • England and Wales
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions.Summit Therapeutics PLC • April 13th, 2018 • Pharmaceutical preparations
AWARD/CONTRACT 1. THIS CONTRACT IS A RATED ORDER UNDER DPAS (15 CFR 700) Ø RATING PAGE OF PAGES 1 63 2. CONTRACT (Proc. Inst. Ident.) NO.HHSO100201700014C 3. EFFECTIVE DATESee Block 20C 4. REQUISITION/PURCHASE REQUEST/PROJECT NO.OS202400 6. ISSUED BY CODE ASPR-BARDA 6. ADMINISTERED BY (If other than Item 5) CODE ASPR-BARDA02 ASPR-BARDAO’NEILL HOUSE OFFICE BUILDINGWashington DC 20515 US DEPT OF HEALTH & HUMAN SERVICESASST SEC OF PREPAREDNESS & RESPONSEACQ MANAGEMENT, CONTRACTS, & GRANTSO’NEILL HOUSE OFFICE BUILDINGWashington DC 20515 7. NAME AND ADDRESS OF CONTRACTOR (No., Street, City, County, State and ZIP Code) SUMMIT (OXFORD) LIMITED 1510803[**]; 85B PARK DRIVE85B PARK DRIVEMILTON PARKABINGDON OXFORDSHIRE OX14 8. DELIVERY ¨ FOB ORIGIN x OTHER (See below) 9. DISCOUNT FOR PROMPT PAYMENT 10. SUBMIT NOTICES(4 copies unless otherwise specified)TO THE ADDRESS SHOWN IN Ø ITEM CODE 1510803 FACILITY CODE 11. SHIP TO/MAKE FOR CODE HHS/OS/ASPR 12. PAYMENT WILL MADE BY CODE DHHS/FMS
ContractSummit Therapeutics Inc. • March 9th, 2023 • Pharmaceutical preparations
DATED 16th November 2015 - and - - and - SECOND VARIATION AGREEMENT relating to the Agreement for the Sponsorship of a Research Programme for the development of small molecule modulators of utrophin for the treatment of Duchenne Muscular Dystrophy...Second Variation Agreement • May 12th, 2016 • Summit Therapeutics PLC • Pharmaceutical preparations • England and Wales
SUMMIT CORPORATION PLC EMI OPTION AGREEMENT «Forename» «Surname»Emi Option Agreement • December 4th, 2014 • Summit Corp PLC • Pharmaceutical preparations
BY SUMMIT CORPORATION PLC (registered number 05197494 whose registered office is at 85b Park Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RY (“the Company”).
May 28, 2021 Michael Donaldson Concord, MA 01742 Dear Michael:Consulting Agreement • May 28th, 2021 • Summit Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
This letter will confirm our discussion concerning the separation of your employment with Summit Therapeutics Inc. (the “Company”) effective on July 2, 2021 (the “Separation Date”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 10th, 2019 • Summit Therapeutics PLC • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of January 9, 2019 by and among Summit Therapeutics plc, a public limited company incorporated in England and Wales with the Registrar of Companies of England and Wales (the “Company”), and the “Investor” named in that certain Securities Purchase Agreement by and among the Company and the Investor (the “Purchase Agreement”). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions..Summit Therapeutics PLC • April 13th, 2018 • Pharmaceutical preparations • England
LICENSE AND COLLABORATION AGREEMENT by and between SUMMIT (OXFORD) LTD and SAREPTA THERAPEUTICS, INC. Dated as of October 3, 2016License and Collaboration Agreement • March 30th, 2017 • Summit Therapeutics PLC • Pharmaceutical preparations • New York
] American Depositary Shares Representing [ ] Ordinary Shares (Par Value £0.01 Per Share) SUMMIT THERAPEUTICS PLC UNDERWRITING AGREEMENTUnderwriting Agreement • February 20th, 2015 • Summit Therapeutics PLC • Pharmaceutical preparations • New York
The ADSs will be evidenced by American Depositary Receipts (“ADRs”) issued pursuant to that certain Deposit Agreement dated [ ], 2015 (the “Deposit Agreement”), by and among the Company, The Bank of New York Mellon, as depositary (the “Depositary”), and all holders and beneficial owners of ADSs issued thereunder. The Ordinary Shares to be issued in connection with, and represented by, the ADSs are hereinafter referred to as the “Underlying Securities.”
EXECUTION Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omitted information. 1...Common Stock Issuance Agreement • January 20th, 2023 • Summit Therapeutics Inc. • Pharmaceutical preparations • New York
DATED 22 November 2013 AGREEMENT FOR THE SPONSORSHIP OF A RESEARCH PROGRAMMESummit Corp PLC • December 4th, 2014 • Pharmaceutical preparations
ContractSummit Therapeutics Inc. • September 18th, 2020 • Pharmaceutical preparations • Delaware
THIS WARRANT AND THE WARRANT SHARES TO BE ISSUED UPON ITS EXERCISE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH HEREIN, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
RESCISSION AGREMENTRescission Agrement • April 21st, 2021 • Summit Therapeutics Inc. • Pharmaceutical preparations
This Rescission Agreement (the “Agreement”) dated as of April 20, 2021 is entered into by and between Summit Therapeutics Inc., a Delaware corporation (the “Company”) and the Investor.
